Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

OBJECTIVES. The purpose of this study was to determine the spectrum of left ventricular hypertrophy and ventricular morphology in adults with hypertrophic cardiomyopathy due to mutations of the beta-myosin heavy-chain gene. BACKGROUND. Although echocardiography is an important test in diagnosing hypertrophic cardiomyopathy, the lack of an independent diagnostic criterion has been an obstacle in determining the full echocardiographic spectrum of this disease. Mutations in the beta-myosin heavy chain gene occur in approximately 50% of familial cases; in members of families with a known mutation, the diagnosis can be made with certainty. METHODS. Echocardiograms from 39 genetically affected and 30 genetically unaffected adult family members over age 16 years from 10 families were analyzed. Left ventricular wall thickness was measured at 10 separate locations, and the presence of systolic anterior motion of the mitral valve, right ventricular hypertrophy and left ventricular morphology was evaluated independently by three separate observers without knowledge of the genetic diagnosis. RESULTS. The mean maximal wall thickness in the genetically affected group was 24 +/- 8 mm (range 11 to 40), compared with 11 +/- 2 mm (range 7 to 16) in the unaffected group (p < 0.0001). Systolic anterior motion of the mitral valve or chordae tendineae with or without leaflet-septal contact was present in 62% of the affected group and in none of the unaffected group. The morphologic finding of reversed septal curvature was present in 79% of the affected group and in none of the unaffected group. Seventy-seven percent of patients in the affected group had a septal/free wall ratio > or = 1.3 compared with 6% in the unaffected group, with a septal/posterior wall ratio > or = 1.3 associated with only a 55% probability of being affected. CONCLUSIONS. The two-dimensional echocardiographic spectrum of hypertrophic cardiomyopathy in a genetically defined adult population is broad. Previous echocardiographic criteria may be too strict to diagnose the disease in some patients who are genetically affected and therefore at risk for adverse events related to the disease. Ultimately, genetic testing may supersede echocardiography in diagnosing hypertrophic cardiomyopathy.

This article has been cited by other articles:

				E. Orenes-Pinero, D. Hernandez-Romero, E. Jover, M. Valdes, G. Y. Lip, and F. Marin Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2011; 12(4): 521 - 530. [Abstract] [PDF]

				J. M. Bos, J. A. Towbin, and M. J. Ackerman Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., July 14, 2009; 54(3): 201 - 211. [Abstract] [Full Text] [PDF]

				S. G. Priori, C. Napolitano, S. E. Humphries, and J. Skipworth CHAPTER 9 Genetics of Cardiovascular Diseases ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				L. C. Afonso, J. Bernal, J. J. Bax, and T. P. Abraham Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. J. Am. Coll. Cardiol. Img., November 1, 2008; 1(6): 787 - 800. [Abstract] [Full Text] [PDF]

				C. Y. Ho, N. K. Sweitzer, B. McDonough, B. J. Maron, S. A. Casey, J.G. Seidman, C. E. Seidman, and S. D. Solomon Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy Circulation, June 25, 2002; 105(25): 2992 - 2997. [Abstract] [Full Text] [PDF]

				A. M. Varnava, P. M. Elliott, C. Baboonian, F. Davison, M. J. Davies, and W. J. McKenna Hypertrophic Cardiomyopathy: Histopathological Features of Sudden Death in Cardiac Troponin T Disease Circulation, September 18, 2001; 104(12): 1380 - 1384. [Abstract] [Full Text] [PDF]

				C. Y. Ho, H. M. Lever, R. DeSanctis, C. F. Farver, J. G. Seidman, and C. E. Seidman Homozygous Mutation in Cardiac Troponin T : Implications for Hypertrophic Cardiomyopathy Circulation, October 17, 2000; 102(16): 1950 - 1955. [Abstract] [Full Text] [PDF]

				M. J. Tyska, E. Hayes, M. Giewat, C. E. Seidman, J. G. Seidman, and D. M. Warshaw Single-Molecule Mechanics of R403Q Cardiac Myosin Isolated From the Mouse Model of Familial Hypertrophic Cardiomyopathy Circ. Res., April 14, 2000; 86(7): 737 - 744. [Abstract] [Full Text] [PDF]

				H. Nakaura, S. Morimoto, F. Yanaga, M. Nakata, H. Nishi, T. Imaizumi, and I. Ohtsuki Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy Am J Physiol Cell Physiol, August 1, 1999; 277(2): C225 - C232. [Abstract] [Full Text] [PDF]

				A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy Hypertension, November 1, 1998; 32(5): 825 - 830. [Abstract] [Full Text] [PDF]

				B. J. Maron, J. H. Moller, C. E. Seidman, G. M. Vincent, H. C. Dietz, A. J. Moss, J. A. Towbin, H. M. Sondheimer, R. E. Pyeritz, G. McGee, et al. Impact of Laboratory Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Diseases: Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome : A Statement for Healthcare Professionals From the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association Circulation, October 6, 1998; 98(14): 1460 - 1471. [Full Text] [PDF]

				R. Anan, H. Shono, A. Kisanuki, S. Arima, S. Nakao, and H. Tanaka Patients With Familial Hypertrophic Cardiomyopathy Caused by a Phe110Ile Missense Mutation in the Cardiac Troponin T Gene Have Variable Cardiac Morphologies and a Favorable Prognosis Circulation, August 4, 1998; 98(5): 391 - 397. [Abstract] [Full Text] [PDF]

				P. P. Dimitrow, D. Czarnecka, K. K. Jaszcz, and J. S. Dubiel Comparison of Left Ventricular Hypertrophy Expression in Patients with Hypertrophic Cardiomyopathy on the Basis of Sex European Journal of Cardiovascular Prevention & Rehabilitation, April 1, 1998; 5(2): 85 - 87. [Abstract] [PDF]

				P. Charron, O. Dubourg, M. Desnos, R. Isnard, A. Hagege, A. Millaire, L. Carrier, G. Bonne, F. Tesson, P. Richard, et al. Diagnostic Value of Electrocardiography and Echocardiography for Familial Hypertrophic Cardiomyopathy in a Genotyped Adult Population Circulation, July 1, 1997; 96(1): 214 - 219. [Abstract] [Full Text]

				C. R. Cannan, G. S. Reeder, K. R. Bailey, L. J. Melton III, and B. J. Gersh Natural History of Hypertrophic Cardiomyopathy : A Population-Based Study, 1976 Through 1990 Circulation, November 1, 1995; 92(9): 2488 - 2495. [Abstract] [Full Text]

				M. Lechin, M. A. Quinones, A. Omran, R. Hill, Q.-T. Yu, H. Rakowski, D. Wigle, C.C. Liew, M. Sole, R. Roberts, et al. Angiotensin-I Converting Enzyme Genotypes and Left Ventricular Hypertrophy in Patients With Hypertrophic Cardiomyopathy Circulation, October 1, 1995; 92(7): 1808 - 1812. [Abstract] [Full Text]

				A.J. Marian and R. Roberts Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy Circulation, September 1, 1995; 92(5): 1336 - 1347. [Full Text]

				K. Schwartz, L. Carrier, P. Guicheney, and M. Komajda Molecular Basis of Familial Cardiomyopathies Circulation, January 15, 1995; 91(2): 532 - 540. [Full Text]